Furthermore, the administration of statins can be effective in portal hypertension.15 By inhibiting RhoA translocation, statins reduce RhoA kinase activity, which counteracts further vasoconstriction.14,16 Moreover, statins improve endothelial dysfunction by enhancing endothelial nitric oxide synthesis activity and nitric oxide availability.14,17 However, information is lacking on the relevance of these effects in the general population, especially in individuals without a history of liver-related diseases. Here, RHOA is linked to portal hypertension.